This is a news story, published by Investor's Business Daily, that relates primarily to Eli Lilly's news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
oral weight loss pill. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Loss Drug Market news, Eli Lilly stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
loss pillInvestor's Business Daily
•Health
Health
70% Informative
Eli Lilly's orforglipron lowered blood sugar and body weight in patients with Type 2 diabetes.
The trials are part of a tight competition to move the booming weight-loss drug business to oral pills.
Pfizer scrapped development of its oral weight loss pill, danuglipron, after one patient experienced potential drug-induced liver injury.
VR Score
68
Informative language
68
Neutral language
50
Article tone
formal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
1
Affiliate links
no affiliate links
Small business owner?
